Interactions between the recipient immune system and the left ventricular assist device surface: Immunological and clinical implications

Annals of Thoracic Surgery

Volumn 75, Issue 6 SUPPL., 2003, Pages

  Itescu, Silviu ^a   John, Ranjit ^a  

^a Coll Phys/Surgs of Columbia Univ ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CD14 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; HLA ANTIBODY; HLA DR3 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESNA; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY;

ALLOIMMUNITY; APOPTOSIS; ARTHRALGIA; ASSISTED CIRCULATION; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL DEATH; CELL LOSS; CELLULAR IMMUNITY; CLINICAL IMMUNOLOGY; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DEVICE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEVER; FOLLOW UP; GRAFT REJECTION; HEART GRAFT; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HOST SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION RISK; INFECTION SENSITIVITY; INTERMETHOD COMPARISON; LYMPHOCYTE PROLIFERATION; MONOCYTE; NAUSEA; PLASMAPHERESIS; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VOMITING;

HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNE SYSTEM;

EID: 0038651165     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00480-6     Document Type: Conference Paper

References (48)

1. Hognes JR. Prototypes, policies and patients. In: Hogness JR, Van Antwerp M, eds. The artificial heart: prototypes, policies and patients. Washingtion, DC: National Academy Press, 1991:1-312.
2. Annual Report of the US Scientific Registry for Organ Transplantation and the Organ Procurement and Transplantation Network, 1990. Washington, DC: US Department of Health and Human Services, 1990.
3. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the Heartmate 1000 IP left ventricular assist device. Ann Thorac Surg 1992;53:1080-90.
4. McCarthy PM, Portner PM, Tobler HG, et al. Clinical experience with the Novacor ventricular assist system: bridge to transplantation and the transition to permanent application. J Thorac Cardiovasc Surg 1991;102:578-87.
5. Oz MC, Argenziano M, Catanese KA, et al. Bridge experience with long-term implantable left ventricular assist devices: are they an alternative to transplantation? Circulation 1997;95:1844-52.
6. Didisheim P. Current concepts of thrombosis and infection in artificial organs. ASAIO J 1994;40:230-7.
7. Wagner WR, Johnson PC, Kormos RL, Griffith BP. Evaluation of bioprosthetic valve-associated thrombus in ventricular assist device patients. Circulation 1993;88:2023-9.
8. Rose EA, Levin HR, Oz MC, et al. Artificial circulatory support with textured interior surfaces. A counterintuitive approach to minimizing thromboembolism. Circulation 1994;50:1187-91.
9. Menconi MJ, Owen T, Dasse KA, Stein G, Lian JB. Molecular approaches to the characterization of cell and blood/biomaterial interactions. J Card Surg 1992;7:177-87.
10. Dasse KA, Chipman SD, Sherman CN, Levine AH, Frazier OH. Clinical experience with textured blood contacting surfaces in ventricular assist devices. ASAIO Trans 1987;33:418-25.
11. Spanier TB, Oz MC, Rose EA, et al. Activation of NF-KB is central to the proinflamatory/procoagulant response in textured surface left ventricular assist device recipients, and may be influenced by anti-imflammatory intervention with aspirin. J Lung Heart Transpl 1997;17:80.
12. Spanier T, Oz M, Levin H, et al. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 1996;112:1090-7.
13. Spanier TB, Rose S, Schmidt AM, Itescu S. Interactions between dentrictic cells and T cells on the surface of left ventricular assist devices leads to a TH2 pattern of cytokine production and B cell hyperreactivity in vivo. Circulation 1996;94(Suppl 8):170.
14. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bc1-2 expression and consequences for AIDS pathogenesis. J Immunol 1998;160:3194-206.
15. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature 1995;373:441-4.
16. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995;373:438-41.
17. Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/Fas ligand interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
18. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991;353:858-1.
19. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fa/APO-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-78.
20. Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996;93:1624-9.
21. Bach JF, Koutouzov S. Immunology: new clues to systemic lupus. Lancet 1997;350(Suppl 3):SIII11.
22. Funauchi M, Ikoma S, Enomoto H, Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol 1998;27:219-24.
23. Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of interleukin 12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthrit Rheum 1998;41:838-44.
24. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas: differential regulation of Fas (CD95) versus Fas ligand expression by Cyclosporin A and FK 506. Int Immunol 1996;8:11017-9.
25. Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transplant Immunol 1993;1:60-5.
26. Joysey VC. Tissue typing, heart and heart-lung transplantation. Br J Biomed Sci 1993;50:272-6.
27. Ratkovec RM, Hammond EH, O'Connell JB, et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch: preliminary results with plasmapharesis. Transplantation 1992;54:651-5.
28. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999;100:II229-35.
29. Itescu S, Tung T, Burke E, Weinberg A, Oz M, Suciu-Foca N, Michler R. Preformed IgG antibodies against major histocompatibility class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998;98:786-93.
30. Liu Z, Colovai AI, Tugulea S, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996;98:1150-7.
31. Tugulea S, Ciubotariu R, Colovai AI, et al. New strategies for early diagnosis of heart allograft rejection. Transplantation 1997;64:842-7.
32. Ciubotariu R, Liu Z, Itescu S, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1997;101:398-405.
33. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996;8:831-6.
34. Mamula MJ, Janeway CA Jr. Do B cells drive the diversification of immune responses? Immunol Today 1993;14:151-4.
35. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant associated coronary artery disease. Transplantation 1996;61:556-72.
36. Glotz D, Haymann J, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). Transplantation 1993;56:335-7.
37. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994;57:553-62.
38. Peraldi M, Akposso K, Hayman J, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996;62:1670-3.
39. McIntyre JA, Higgins N, Britton R, et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting cardiac transplantation. Transplantation 1996;62:691-3.
40. De Marco T, Damon LE, Colombe B, et al. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997;16:360-5.
41. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
42. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992;79:2946-51.
43. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143:4104-9.
44. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulins for therapeutic use (IVIg). Therapeut Immunol 1993;1:269-78.
45. Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (IVIg). Clin Exp Immunol 1993;92:369-72.
46. Blasczyk R, Westhoff U, Grossewilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-90.
47. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993;342:678.
48. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002;105:1214-9.